Last reviewed 2026-05-26 · How we verify

Quadrisol (VEDAPROFEN)

Phase 2 active Small molecule Under review Quality 0/100

Quadrisol (generic name: VEDAPROFEN) is a vedaprofen drug. It is currently in Phase 2 development.

Quadrisol works by inhibiting a specific enzyme or receptor to produce its therapeutic effect.

Quadrisol is a small molecule inhibitor of the Cyclooxygenase-1 enzyme. It belongs to the drug class of inhibitors.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	VEDAPROFEN
Drug class	vedaprofen
Modality	Small molecule
Therapeutic area	Pain
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like a factory with many different machines working together. Quadrisol is like a tool that blocks one of these machines, which helps to reduce inflammation and pain. This allows the body to heal and recover more effectively.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Quadrisol CI brief — competitive landscape report
Quadrisol updates RSS · CI watch RSS

Frequently asked questions about Quadrisol

What is Quadrisol?

Quadrisol (VEDAPROFEN) is a vedaprofen drug.

How does Quadrisol work?

Quadrisol works by inhibiting a specific enzyme or receptor to produce its therapeutic effect.

What is the generic name of Quadrisol?

VEDAPROFEN is the generic (nonproprietary) name of Quadrisol.

What drug class is Quadrisol in?

Quadrisol belongs to the vedaprofen class. See all vedaprofen drugs at /class/vedaprofen.

What development phase is Quadrisol in?

Quadrisol is in Phase 2.

Drug class: All vedaprofen drugs
Therapeutic area: All drugs in Pain

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing